Biogen needs a win with its Tecfidera follow-on, while Kalvista hopes to make HAE where Biocryst failed.
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
Shutdown or no, drug reviews are still under way, giving the sector something to look forward to as 2019 kicks off.
Biotech’s propensity to manipulate clinical datasets to show significance where none exists must be curbed, but a plan to raise the p value threshold looks like a way of…
ALKS 5461 is headed back to the clinic or scrapheap, raising questions over whether Alkermes should remain in mental health drug development.
As one headache for Acadia eases another begins, with unconvincing results from a mid-stage depression trial of Nuplazid.
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…
Alkermes’ two most advanced pipeline assets must prove their worth in the coming months: ALKS 5461 by persuading an FDA panel, and ALKS 3831 by succeeding in phase III.
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.